Allogeneic Stem Cell Transplantation Using Myeloablative and Reduced-Intensity Conditioning in Patients with Major Histocompatibility Complex Class II Deficiency

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 6, 2010, Pages 818-823

  Al Mousa, Hamoud ^a   Al Shammari, Zamil ^a   Al Ghonaium, Abdulaziz ^a   Al Dhekri, Hasan ^a   Al Muhsen, Saleh ^a   Al Saud, Bander ^a   Arnaout, Rand ^a   Al Seraihy, Amal ^b   Al Jefri, Abdullah ^b   Al Ahmari, Ali ^b   Ayas, Mouhab ^b   El Solh, Hassan ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Conditioning; Immunodeficiency; Major histocompatibility complex class II deficiency; Stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BARE LYMPHOCYTE SYNDROME; CHILD; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; HLA MATCHING; HUMAN; IMMUNE RESPONSE; INFANT; MALE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; WHOLE BODY RADIATION;

BLOOD CELL COUNT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; INFANT, NEWBORN; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77952581213     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.01.002     Document Type: Article

References (14)

1. Griscelli C., Lisowska-Grospierre B., Mach B. Combined immunodeficiency with defective expression of MHC class P{cyrillic} genes. Immunodef Rev 1989, 1:135-153.
2. Klein C., Lisowska-Grospierre B., LeDeist F., et al. Major histocompatibility complex class P{cyrillic} deficiency: clinical manifestations, immunological features and outcome. J Pediatr 1993, 123:921-928.
3. Saleem M.A., Arkwright P.D., Davies E.G., et al. Clinical course of patients with major histocompatibility complex class P{cyrillic} deficiency. Arch Dis Child 2000, 83:356-359.
4. Villard J., Masternak K., Lisowska-Grospierre B., et al. MHC class II deficiency: a disease of gene regulation. Medicine 2001, 80:405-418.
5. Klein C., Cavazzana-Calvo M., Le Deist F., et al. Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients. Blood 1995, 85:580-587.
6. Antoine C., Muller Cant A., Muller S., Cant A. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of European experience 1968-99. Lancet 2003, 361:553-560.
7. Buckley R.H., Fischer A. Bone marrow transplantation for primary immunodeficiency diseases. Primary Immunodeficiency Disease 1999, 459-475. Oxford University Press, Oxford, UK. H.D. Ochs, C.E. Smith, J.M. Puck (Eds.).
8. Renella R., Picard C., Neven B., et al. Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and preexisting viral infections. Br J Haematol 2006, 134:510-516.
9. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
10. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
11. Childs R., Clave E., Contentin N., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999, 94:3234-3241.
12. Amrolia P., Gaspar H.B., Hassan A., et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000, 96:1239-1246.
13. Rao K., Amrolia P.J., Jones A., et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005, 105:879-885.
14. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.